Suppliers / Zhejiang Guobang Pharmaceutical

Zhejiang Guobang Pharmaceutical

China Updated 9 July 2026

Zhejiang Guobang Pharmaceutical is an API manufacturer based in China. It holds 13 active US drug master files and 13 valid CEPs across a filed portfolio of 18 molecules. Its GMP standing is certified by EMA and US FDA. Its most recent recorded inspection, by US FDA, closed on 3 March 2025 as VAI.

13
active US DMFs
13
valid CEPs
3
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 3 March 2025 VAI US FDA
  • 10 January 2020 VAI US FDA
  • 24 September 2015 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Shangyu, China Not on file
Shaoxing, China Not on file
China, China 3008617115

What they file, and where

Molecule Regulators Docs
Ciprofloxacin EDQM, SFDA (Saudi Arabia), US FDA 5
Clarithromycin EDQM, SFDA (Saudi Arabia), US FDA 4
Azithromycin EDQM, US FDA 2
Moxifloxacin EDQM, US FDA 2
Rivaroxaban EDQM, US FDA 2
Apixaban US FDA 1
Brexpiprazole US FDA 1
Diclazuril For Veterinary Use EDQM 1
Edoxaban US FDA 1
Enrofloxacin For Veterinary Use EDQM 1
Show all 18 molecules on file
Guanfacine US FDA 1
Lanthanum Carbonate US FDA 1
Macitentan US FDA 1
Marbofloxacin For Veterinary Use EDQM 1
Roxithromycin EDQM 1
Solifenacin Succinate EDQM 1
Topiroxostat US FDA 1
Vonoprazan US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
EMA None 2
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Zhejiang Guobang Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 3 March 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates